Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics in cancer. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination with other drugs, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.
This press release may contain forward-looking statements within the
meaning of Canadian and U.S. securities laws. Such statements include, but
are not limited to, statements relating to: our research program plans, our
plans to conduct clinical trials, the successful and timely completion of
clinical studies and the regulatory approval process, our ability to fund
future research, our plans to obtain partners to assist in the further
development of our product candidates, the establishment of corporate
alliances, the Company's plans, objectives, expectations and intentions and
other statements including words such as "continue", "believe", "plan",
"expect", "intend", "will", "should", "may", and other similar expressions.
Such statements reflect our current views with respect to future events and
are subject to risks and uncertainties and are necessarily based upon a
number of estimates and assumptions that, while considered reasonable by us
are inherently subject to significant business, economic, competitive,
political and social uncertainties and contingencies. Many factors cou
|SOURCE Lorus Therapeutics Inc.|
Copyright©2008 PR Newswire.
All rights reserved